Indication of metronomic chemotherapy for metastatic breast cancer: clinical outcomes and responsive subtypes

Kontani,Keiichi; Hashimoto,Shin‑Ichiro; Murazawa,Chisa; Norimura,Shoko; Tanaka,Hiroaki; Ohtani,Masahiro; Fujiwara‑Honjo,Naomi; Date,Manabu; Teramoto,Koji; Houchi,Hitoshi; Yokomise,Hiroyasu

doi:10.3892/mco.2016.841

Indication of metronomic chemotherapy for metastatic breast cancer: clinical outcomes and responsive subtypes

Authors:
- Keiichi Kontani
- Shin‑Ichiro Hashimoto
- Chisa Murazawa
- Shoko Norimura
- Hiroaki Tanaka
- Masahiro Ohtani
- Naomi Fujiwara‑Honjo
- Manabu Date
- Koji Teramoto
- Hitoshi Houchi
- Hiroyasu Yokomise
View Affiliations

Affiliations: Department of Thoracic, Breast and Endocrine Surgery, Kagawa University Faculty of Medicine, Miki, Kagawa 761‑0793, Japan, Department of Surgery, Japanese Red Cross Hospital, Takamatsu, Kagawa 760‑0017, Japan, Department of Pharmacy, Kagawa University Hospital, Miki, Kagawa 761‑0793, Japan, Kagawa Health Service Association, Health Care Center, Takamatsu, Kagawa 761‑8071, Japan, Department of Radiology, Osaka Neurosurgery Hospital, Takamatsu, Kagawa 761‑8083, Japan, Department of Surgery, Date Hospital, Takamatsu, Kagawa 760‑0076, Japan, Department of Surgery, Shiga University of Medical Science, Otsu, Shiga 520‑2191, Japan
Published online on: March 30, 2016 https://doi.org/10.3892/mco.2016.841
Pages: 947-953

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The survival of patients with metastatic breast cancer (MBC) has not improved, despite recent advances in therapeutic strategies. This is mainly due to the fact that cytotoxic agents cannot be administered over a long period, even if they exhibit favorable activity, due to treatment‑related side effects or acquisition of tumor resistance to the administered agents. Thus, the development of therapeutic strategies that may be used over a long time period is required to improve survival. We assessed the availability and clinical outcomes of metronomic chemotherapy, which is defined as continuous or frequent treatment with low doses of cytotoxic drugs. A total of 80 patients with MBC received chemotherapy in the metastatic setting, and the clinicopathological factors and clinical outcomes were retrospectively compared between 52 patients who received metronomic regimens and 28 patients who received other cytotoxic regimens. As regards clinical outcomes, the median time‑to‑treatment failure (TTF) and overall survival (OS) were significantly longer in the metronomic group compared with those in the non‑metronomic group (TTF, 15 vs. 4 months, P=0.0001; and OS, 53 vs. 28 months P=0.0012, respectively). In the metronomic group, none of the 18 patients who responded to the regimen had triple‑negative (TN) cancer (17 had luminal‑type tumors and 1 had a human epidermal factor receptor 2‑type tumor). Furthermore, TTF and OS were significantly longer in patients with non‑TN cancer compared with those in patients with TN cancer in the metronomic group (TTF, 16 vs. 7 months, P=0.0014; and OS, 108 vs. 20 months, P=0.000007, respectively). The proportion of patients who experienced treatment‑related adverse events was significantly lower in the metronomic group compared with that in the non‑metronomic group (36.5 vs. 61.5%, respectively; P=0.038). In conclusion, metronomic chemotherapy is a viable option for luminal‑type MBC in terms of effectiveness and minimal toxicity, regardless of metastatic sites or prior treatment. However, an alternative treatment is required for TN cancer.

View Figures

View References

1	Smith I and Chua S: Medical treatment of early breast cancer. IV: Neoadjuvant treatment. BMJ. 332:223–224. 2006. View Article : Google Scholar : PubMed/NCBI
2	Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, Natoli G, Terzoli E, Cognetti F and Giannarelli D: Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients. Cancer. 106:2337–2344. 2006. View Article : Google Scholar : PubMed/NCBI
3	Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, et al: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res. 8:1073–1079. 2002.PubMed/NCBI
4	O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol. 20:2812–2823. 2002. View Article : Google Scholar : PubMed/NCBI
5	Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, et al: Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 26:3950–3957. 2009. View Article : Google Scholar
6	Nielsen DL, Bjerre KC, Jakobsen EH, Cold S, Stenbygaard L, Sørensen PG, Kamby C, Møller S, Jørgensen CLT and Andersson M: Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: A randomized, phase III study by the Danish Breast Cancer Cooperative Group. J Clin Oncol. 29:4748–4754. 2011. View Article : Google Scholar : PubMed/NCBI
7	Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
8	Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V and Rugo HS: RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 29:4286–4293. 2011. View Article : Google Scholar : PubMed/NCBI
9	Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 29:1252–1260. 2011. View Article : Google Scholar : PubMed/NCBI
10	Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, et al: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet. 377:914–923. 2011. View Article : Google Scholar : PubMed/NCBI
11	Kontani K, Hashimoto SI, Murazawa C, Norimura S, Tanaka H, Ohtani M, Fujiwara-Honjo N, Date M, Houchi H and Yokomise H: Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more. Mol Clin Oncol. 1:225–230. 2013.PubMed/NCBI
12	Kontani K, Hashimoto S, Murazawa C, Norimura S, Tanaka H, Ohtani M, Fujiwara-Honjo N, Date M, Teramoto K, Houchi H and Yokomise H: Factors responsible for long-term survival in metastatic breast cancer. World J Surg Oncol. 12:3442014. View Article : Google Scholar : PubMed/NCBI
13	Oostendorp LJ, Stalmeier PF, Donders AR, van der Graaf WT and Ottevanger PB: Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: A systematic review. Lancet Oncol. 12:1053–1061. 2011. View Article : Google Scholar : PubMed/NCBI
14	Kerbel RS and Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 4:423–436. 2004. View Article : Google Scholar : PubMed/NCBI
15	Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, et al: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 13:73–80. 2002. View Article : Google Scholar : PubMed/NCBI
16	Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nolè F, et al: Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: Antitumor activity and biological effects. Ann Oncol. 17:232–238. 2006. View Article : Google Scholar : PubMed/NCBI
17	Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, et al: Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol. 28:723–730. 2010. View Article : Google Scholar : PubMed/NCBI
18	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
19	US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdfAccessed. January 14–2014
20	Jassem J, Pieńkowski T, Płuzańska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, et al: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol. 19:1707–1715. 2001.PubMed/NCBI
21	Bonneterre J, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre ME, Delozier T, Mayer F, Culine S, Dohoulou N and Bendahmane B: Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer. 91:1466–1471. 2004.PubMed/NCBI
22	Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK and Wood WC: Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol. 21:588–592. 2003. View Article : Google Scholar : PubMed/NCBI
23	Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 18:724–733. 2000.PubMed/NCBI